{"id":"hydrocodone-apap-w-placebo-prn","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Constipation"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Dizziness"},{"rate":"15-25","effect":"Drowsiness"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hepatotoxicity (acetaminophen)"}]},"_chembl":{"chemblId":"CHEMBL1201470","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocodone acts as a mu opioid receptor agonist, modulating pain signals in the brain and spinal cord. Acetaminophen works through a separate mechanism involving inhibition of cyclooxygenase enzymes and prostaglandin production. The combination provides synergistic pain relief. The 'w placebo PRN' notation indicates this is a formulation used in a clinical trial or research setting with placebo control and as-needed dosing.","oneSentence":"Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain perception, while acetaminophen (APAP) inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:55.468Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate pain (marketed combination indication)"}]},"trialDetails":[{"nctId":"NCT00385684","phase":"PHASE4","title":"Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2007-10","conditions":"Alzheimer Disease, Dementia, Dementia, Vascular","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lortab"],"phase":"marketed","status":"active","brandName":"hydrocodone/APAP w placebo PRN","genericName":"hydrocodone/APAP w placebo PRN","companyName":"VA Office of Research and Development","companyId":"va-office-of-research-and-development","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain perception, while acetaminophen (APAP) inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Moderate pain (marketed combination indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}